1-8 of 8
Xiang S. Ye
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy

Free
Jian Du, Lei Yan, Raquel Torres, Xueqian Gong, Huimin Bian, Carlos Marugán, Karsten Boehnke, Carmen Baquero, Yu-Hua Hui, Sonya C. Chapman, Yanzhu Yang, Yi Zeng, Sarah M. Bogner, Robert T. Foreman, Andrew Capen, Gregory P. Donoho, Robert D. Van Horn, Darlene S. Barnard, Jack A. Dempsey, Richard P. Beckmann, Mark S. Marshall, Li-Chun Chio, Yuewei Qian, Yue W. Webster, Amit Aggarwal, Shaoyou Chu, Shobha Bhattachar, Louis F. Stancato, Michele S. Dowless, Phillip W. Iversen, Jason R. Manro, Jennie L. Walgren, Bartley W. Halstead, Matthew Z. Dieter, Ricardo Martinez, Shripad V. Bhagwat, Emiko L. Kreklau, Maria Jose Lallena, Xiang S. Ye, Bharvin K.R. Patel, Christoph Reinhard, Gregory D. Plowman, David A. Barda, James R. Henry, Sean G. Buchanan, Robert M. Campbell
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2207–2219.
https://doi.org/10.1158/1535-7163.MCT-18-0529
Published: 02 December 2019
View article titled, Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy
Open the PDF for Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor Efficacy in another window
Includes: Supplementary data
Journal Articles

A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models

Free
Xiang S. Ye, Li Fan, Robert D. Van Horn, Ryuichiro Nakai, Yoshihisa Ohta, Shiro Akinaga, Chikara Murakata, Yoshinori Yamashita, Tinggui Yin, Kelly M. Credille, Gregory P. Donoho, Farhana F. Merzoug, Heng Li, Amit Aggarwal, Kerry Blanchard, Eric H. Westin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (11): 2463–2472.
https://doi.org/10.1158/1535-7163.MCT-15-0241
Published: 03 November 2015
View article titled, A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models
Open the PDF for A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models in another window
Includes: Supplementary data
Journal Articles

A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models

Free
Tinggui Yin, Maria J. Lallena, Emiko L. Kreklau, Kevin R. Fales, Santiago Carballares, Raquel Torrres, Graham N. Wishart, Rose T. Ajamie, Damien M. Cronier, Phillip W. Iversen, Timothy I. Meier, Robert T. Foreman, Douglas Zeckner, Sean E. Sissons, Bart W. Halstead, Aimee B. Lin, Gregory P. Donoho, Yuewei Qian, Shuyu Li, Song Wu, Amit Aggarwal, Xiang S. Ye, James J. Starling, Richard B. Gaynor, Alfonso de Dios, Jian Du
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (6): 1442–1456.
https://doi.org/10.1158/1535-7163.MCT-13-0849
Published: 04 June 2014
View article titled, A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models
Open the PDF for A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models in another window
Includes: Supplementary data
Journal Articles

Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity

Free
Robert M. Campbell, Bryan D. Anderson, Nathan A. Brooks, Harold B. Brooks, Edward M. Chan, Alfonso De Dios, Raymond Gilmour, Jeremy R. Graff, Enrique Jambrina, Mary Mader, Denis McCann, Songqing Na, Stephen H. Parsons, Susan E. Pratt, Chuan Shih, Louis F. Stancato, James J. Starling, Courtney Tate, Juan A. Velasco, Yong Wang, Xiang S. Ye
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2014) 13 (2): 364–374.
https://doi.org/10.1158/1535-7163.MCT-13-0513
Published: 09 February 2014
View article titled, Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity
Open the PDF for Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity in another window
Includes: Supplementary data
Journal Articles

Abstract A104: A screening method for the identification of potentially effective drug-drug combinations reveals a synergistic interaction between Aurora-A inhibitor MK-5108 and Bcl-xL inhibitor navitoclax.

Free
Xueqian Gong, Shaoling Jin, Farhana Merzoug, Xiang S. Ye, MaryJo Lallena, Jian Du, Yue Webster, Xiwen Ma, Christoph Reinhard, Phillip Iversen, Sean G. Buchanan
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A104.
https://doi.org/10.1158/1535-7163.TARG-13-A104
Published: 01 November 2013
View article titled, Abstract A104: A screening method for the identification of potentially effective drug-drug combinations reveals a synergistic interaction between Aurora-A inhibitor MK-5108 and Bcl-xL inhibitor navitoclax.
Journal Articles

Abstract B229: TBKI kinase inhibition blocks RANTES secretion and exhibits minimal tumor growth inhibition in oncogenic Ras-driven tumor models.

Free
Robert Van Horn, Tinggui Yin, Xiaoyi Zhang, Chunping Yu, Youyan Zhang, Xue-Qian Gong, Sean Buchanan, Xiang S. Ye, William McMillen, David Barda, Sheng-Bin Peng
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B229.
https://doi.org/10.1158/1535-7163.TARG-13-B229
Published: 01 November 2013
View article titled, Abstract B229: TBKI kinase inhibition blocks RANTES secretion and exhibits minimal tumor growth inhibition in oncogenic Ras-driven tumor models.
Journal Articles

Abstract A47: Circulating tumor cell (CTC) assay development for detection of phosphohistone H3 (pHH3) as a clinical pharmacodynamic (PD) marker for LY2523355, an Eg5 kinesin inhibitor.

Free
Suzane L. Um, S. Betty Yan, Victoria L. Peek, Lei Yan, Xiang S. Ye, Eric H. Westin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): A47.
https://doi.org/10.1158/1535-7163.TARG-11-A47
Published: 12 November 2011
View article titled, Abstract A47: Circulating tumor cell (CTC) assay development for detection of phosphohistone H3 (pHH3) as a clinical pharmacodynamic (PD) marker for LY2523355, an Eg5 kinesin inhibitor.
Journal Articles

Abstract A62: A novel Eg5 inhibitor that causes mitotic arrest leading to rapid cancer cell death shows broad‐spectrum antitumor activity in preclinical xenograft tumor models

Free
Xiang S. Ye, Li Fan, Robert Van Horn, Tinggui Yin, Ryuichiro Nakai, Yoshihisa Ohta, Kelly Credille, Gregory Donoho, Shiro Akinaga, Chikara Murakata, Everett Perkins, Scott Ocheltree, Yoshinori Yamashita, Kerry Blanchard, Eric Westin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A62.
https://doi.org/10.1158/1535-7163.TARG-09-A62
Published: 10 December 2009
View article titled, Abstract A62: A novel Eg5 inhibitor that causes mitotic arrest leading to rapid cancer cell death shows broad‐spectrum antitumor activity in preclinical xenograft tumor models